TWI613191B - 阿普斯特之新穎型式及其製造方法 - Google Patents

阿普斯特之新穎型式及其製造方法 Download PDF

Info

Publication number
TWI613191B
TWI613191B TW105127548A TW105127548A TWI613191B TW I613191 B TWI613191 B TW I613191B TW 105127548 A TW105127548 A TW 105127548A TW 105127548 A TW105127548 A TW 105127548A TW I613191 B TWI613191 B TW I613191B
Authority
TW
Taiwan
Prior art keywords
apster
temperature
mixture
suspension
crystalline
Prior art date
Application number
TW105127548A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718485A (zh
Inventor
方曉萍
羅偉碩
王冠勛
林育生
胡聰成
黃原章
Original Assignee
台灣神隆股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 台灣神隆股份有限公司 filed Critical 台灣神隆股份有限公司
Publication of TW201718485A publication Critical patent/TW201718485A/zh
Application granted granted Critical
Publication of TWI613191B publication Critical patent/TWI613191B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW105127548A 2015-08-28 2016-08-26 阿普斯特之新穎型式及其製造方法 TWI613191B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562211280P 2015-08-28 2015-08-28
US62/211,280 2015-08-28
US201662279147P 2016-01-15 2016-01-15
US62/279,147 2016-01-15

Publications (2)

Publication Number Publication Date
TW201718485A TW201718485A (zh) 2017-06-01
TWI613191B true TWI613191B (zh) 2018-02-01

Family

ID=58097541

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105127548A TWI613191B (zh) 2015-08-28 2016-08-26 阿普斯特之新穎型式及其製造方法

Country Status (9)

Country Link
US (1) US9765026B2 (OSRAM)
EP (1) EP3341360A4 (OSRAM)
JP (1) JP2018528948A (OSRAM)
KR (1) KR20180036791A (OSRAM)
CN (1) CN107922332A (OSRAM)
CA (1) CA2994217A1 (OSRAM)
IL (1) IL257195A (OSRAM)
TW (1) TWI613191B (OSRAM)
WO (1) WO2017039537A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174685A1 (en) * 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
US10544097B2 (en) * 2015-08-27 2020-01-28 Msn Laboratories Private Limited Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
CN106977444B (zh) * 2016-01-18 2021-10-08 重庆医药工业研究院有限责任公司 一种阿普斯特无定型的制备方法
HUE065223T2 (hu) * 2016-03-30 2024-05-28 Sarudbhava Formulations Private Ltd Apremilaszt gyógyszerkészítményei
CN107686461A (zh) * 2016-08-04 2018-02-13 广东东阳光药业有限公司 阿普斯特的溶剂化物及其制备方法和用途
WO2019021303A1 (en) * 2017-07-23 2019-01-31 Alkem Laboratories Limited NOVEL PROCESS FOR THE PREPARATION OF APREMILAST IN AMORPHOUS FORM
CN108440381A (zh) * 2018-03-15 2018-08-24 威海迪素制药有限公司 一种阿普斯特新晶型h及其制备方法
EP4330230A1 (en) * 2021-04-26 2024-03-06 Amgen Inc. Process for synthesizing apremilast
WO2023120466A1 (ja) * 2021-12-23 2023-06-29 沢井製薬株式会社 アプレミラスト水和物含有製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2009120167A1 (en) * 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2014072259A1 (en) * 2012-11-08 2014-05-15 Ratiopharm Gmbh Composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2007053503A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
MX2011012122A (es) * 2009-05-14 2012-02-28 Tianjin Hemay Bio Tech Co Ltd Derivados de tiofeno.
EP2723717A2 (en) * 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
IN2014MU01283A (OSRAM) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
CN104447445B (zh) 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
MX2017015151A (es) 2015-05-26 2018-08-15 Lupin Ltd Un proceso mejorado para la preparación de apremilast y novedosos polimorfos del mismo.
BR112017026560A2 (pt) * 2015-06-09 2018-08-14 Dr Reddys Laboratories Ltd processo para preparação de apremilast e seus intermediários.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2009120167A1 (en) * 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2014072259A1 (en) * 2012-11-08 2014-05-15 Ratiopharm Gmbh Composition

Also Published As

Publication number Publication date
US9765026B2 (en) 2017-09-19
WO2017039537A1 (en) 2017-03-09
EP3341360A1 (en) 2018-07-04
EP3341360A4 (en) 2019-01-23
TW201718485A (zh) 2017-06-01
KR20180036791A (ko) 2018-04-09
CA2994217A1 (en) 2017-03-09
CN107922332A (zh) 2018-04-17
IL257195A (en) 2018-03-29
US20170057916A1 (en) 2017-03-02
JP2018528948A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
TWI613191B (zh) 阿普斯特之新穎型式及其製造方法
JP5129132B2 (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾル−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの塩
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2024123096A (ja) （２ｓ，３ｓ）－メチル ７－フルオロ－２－（４－フルオロフェニル）－３－（１－メチル－１ｈ－１，２，４－トリアゾール－５－イル）－４－オキソ－１，２，３，４－テトラヒドロキノリン－５－カルボキシレートのコフォーマー塩、およびそれらを製造する方法
JP2020512380A (ja) ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１Ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−Ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態
CN102985416B (zh) 制备凝血酶特异性抑制剂的方法
JP2007308494A (ja) 結晶イマチニブ塩基及びその製造方法
WO2012002538A1 (ja) 光学活性ジアミン誘導体の塩の製造方法
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
JP2008179645A (ja) ピリダジノン誘導体の純粋なエナンチオマーの取得方法
JP7117415B2 (ja) （４ｓ）－４－［４－シアノ－２－（メチルスルホニル）フェニル］－３，６－ジメチル－２－オキソ－１－［３－（トリフルオロメチル）フェニル］－１，２，３，４－テトラヒドロピリミジン－５－カルボニトリルの製造方法
US20250163086A1 (en) Crystalline Forms
JP2023154056A (ja) エパルレスタットを調製する方法
SK50032014U1 (sk) Kryštalický dihydrát bilastínu
TW201829420A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
JP2025069143A (ja) ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
JP2012506367A (ja) 結晶性モンテルカストの塩
US20100036164A1 (en) Preparation of armodafinil form i
WO2004089933A1 (ja) フルオロベンズアミド誘導体の新規結晶
EA044016B1 (ru) Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения
KR20190027819A (ko) 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드 다형체 형태의 제조 방법